← Back to Search

Ascorbic Acid for Aging

N/A
Waitlist Available
Led By Christopher R Martens, Ph.D.
Research Sponsored by University of Delaware
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18-29 or 55-79 years old
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 30 minutes post-infusion
Awards & highlights

Study Summary

Aging is the primary risk factor for Alzheimer's disease (AD), which is a rapidly growing public health concern. Understanding the mechanisms of normal brain aging may provide insight into the factors linking advancing age to increased risk for AD and thereby lead to new therapeutic targets for preventing or slowing AD progression. Cardiovascular changes, including impaired cerebrovascular function, occur with aging and may increase risk for AD; however, the mechanisms by which cerebrovascular function becomes impaired in older adults are incompletely understood. The overall goal of this project is to examine potential mechanisms of age-related declines in cerebrovascular function in humans. The investigators hypothesize that brain macro-vascular endothelial dysfunction, secondary to oxidative stress, plays an important role in mediating age-related changes in brain blood flow and cerebrovascular reactivity. The results of this pilot study have the potential to identify novel targets of cerebrovascular aging and will help guide the design of future clinical trials aimed at improving cerebral blood flow in older adults.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 30 minutes post-infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 30 minutes post-infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in internal carotid artery (ICA) diameter after acute infusion of the antioxidant ascorbic acid
Secondary outcome measures
Change from baseline in middle cerebral artery (MCA) diameter after acute infusion of the antioxidant ascorbic acid

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Ascorbic AcidActive Control1 Intervention
Ascorbic acid will be measured into sterile syringes by the research nurse and infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline or lactated ringers followed by a "drip-infusion" of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline.
Group II: PlaceboPlacebo Group1 Intervention
Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.

Find a Location

Who is running the clinical trial?

University of DelawareLead Sponsor
154 Previous Clinical Trials
25,177 Total Patients Enrolled
2 Trials studying Aging
142 Patients Enrolled for Aging
Christopher R Martens, Ph.D.Principal InvestigatorUniversity of Delaware
3 Previous Clinical Trials
106 Total Patients Enrolled
2 Trials studying Aging
42 Patients Enrolled for Aging

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Mechanisms of Impaired Brain Blood Flow With Aging
Christopher Martens 2017. "Mechanisms of Impaired Brain Blood Flow With Aging". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03775382.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top